Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Presse Medicale (Paris, France : 1983)|January 20, 1996
[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases]A Votte, F Iglicki, F Sévenet, et al.
Bone Marrow Transplantation|August 1, 1996
Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphomaP Colombat, M Delain, I Desbois, et al.
British Journal of Haematology|January 1, 1995
Human recombinant granulocyte-macrophage colony stimulating factor (hrGM-CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: a pilot studyX Troussard, M Macro, B Vie, et al.
Presse Medicale (Paris, France : 1983)|May 5, 1990
[Peripheral T-cell malignant lymphomas. Clinical, morphologic and developmental features in 22 cases]A Delmer, S Caulet, F Bryard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'AdulteP Brice, Y Bastion, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trialA Ravaud, C Chevreau, L Cany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2007
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapyT El Gnaoui, J Dupuis, K Belhadj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patientsV Dieras, P Bougnoux, T Petit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancerD Cunningham, B Sirohi, A Pluzanska, et al.
Pageof 1